Purpose: Intracytoplasmic sperm injection (ICSI) of some sibling oocytes may have a beneficial effect in couples
INTRODUCTION
Originally, intracytoplasmic sperm injection (ICSI) was developed for treatment of male-factor infertility (1) . It was subsequently discovered that when there is total fertilization failure in an in vitro fertilization (IVF) cycle, subsequent IVF with ICSI may lead to fertilization and pregnancy (1) . Therefore, IVF-ICSI was advocated for such cases with a normal spermatogram. For a woman going through the physical, emotional, and financial burden of an IVF cycle, total fertilization failure is devastating. Such women may have had many oocytes retrieved and it may be advisable to do ICSI on some of the retrieved oocytes. If there is total fertilization failure of inseminated oocytes, fertilization may be achieved with oocytes subjected to ICSI in the same cycle. This concept has led four groups to investigate the place of ICSI in IVF cycles done for non-male-factor infertility (2-5). All investigators used random allocation of retrieved oocytes to IVF without or with ICSI. Comparison of the fertilization and embryo development of these sibling oocytes is providing some answers to the place of ICSI in all IVF cycles, including those done for tubal factor, infertility of undetermined cause, endometriosis, and so forth. In this article, we have reviewed all parameters in the four reports in order to provide a clearer picture.
REVIEW OF THE METHODOLOGY
The four studies were done in the last 6 years (2-5). (5) had one case of oocyte donation (without male factor). All investigators utilized a standard gonadotropinreleasing hormone (GnRH) long-term down-regulation with subsequent human menopausal gonadotropin (hMG) [or pure follicle-Stimulating hormone (FSH)]. Intracytoplasmic sperm injection was performed using standard techniques described previously (1) . In all four studies, some of the oocytes were randomly allotted to ICSI. The results are reported as fertilization rate per oocyte assigned to each treatment group. In the case of ICSI, only oocytes at metaphase II stage were injected; therefore, some oocytes were not injected because they were either immature or postmature, but they were still counted so that a bias was not created in favor of ICSI. However, three of the four studies also reported their fertilization rate per mature injected oocyte (Table I) . The four groups appeared to have a fairly successful IVF-ICSI program as far as pregnancy rates were concerned. However, pregnancy rates are not reported here as a mixture of embryos resulting from the two treatments were transferred. Table I shows the ICSI fertilization rate per mature oocyte injected. It can be seen that with progression of the year of study there has been an improvement in fertilization rate, ranging from 63% to 81.7%. Table II compares the fertilization rates based on number of oocytes assigned to treatments. The earliest study reported in 1995 (2) showed no difference in fertilization rate based on the number of oocytes assigned to treatments (50.7% for standard IVF vs. 50% for ICSI). The second study reported in 1997 (3) showed a difference in fertilization rate between IVF and ICSI, that is, 54% versus 60.4%, respectively, but this was not significant. The third study done in 1998 (4) showed a difference in fertilization rate between IVF insemination and ICSI (52.5% vs. 65.6%) that reached a statistical significance (P Ͻ 0.01). The last study of Khamsi et al. (5) also showed a highly significant difference in fertilization rate between IVF insemination and ICSI (57.2% vs. 71.3%; P ϭ 0.005).
REVIEW OF THE OUTCOME OF THE TRIALS
The results of good and fair embryo formation are shown in Table III (5), respectively. The similarity between these two studies is most interesting.
There was one factor that all four studies were in agreement, that is, the difference in the incidence of total fertilization failure between the two groups. The first three investigators reported a total fertilization failure of 22.7%, 11.4%, and 6.8%, respectively, for standard IVF insemination and no fertilization failure for the ICSI group (Table IV) . Khamsi et al. (5) , however, reported a fertilization failure of 14.3% (5/ 35) and low fertilization rate of 20.0% (7/35) for IVF (total 34.3%; 12/35), and fertilization failure of 2.9% (1/35) for ICSI. 
CONCLUSION BASED ON THE FOUR TRIALS
The four controlled and prospective trials are unanimous in their conclusion that if some of the sibling oocytes are subjected to ICSI, we can avoid the problem of total fertilization failure with conventional IVF insemination, that is, no embryo transfer in an IVF cycle. Considering that often there are many oocytes retrieved, it seems logical to subject some of the oocytes to ICSI. Chronologically, the last two of the four studies showed statistically significant benefit of ICSI both in fertilization and good-fair embryo development. The failure of the earlier studies may be related to improvement in the ICSI technique over the last 5 years. This is demonstrated by the fact that fertilization rate per mature injected oocyte was 63% in the first study and increased to 81.7% in the last study.
The above studies point to the benefit of performing ICSI on some of retrieved oocytes regardless of the cause of infertility. Are there any disadvantages to this proposal? Does the addition of ICSI to standard IVF increase the chance of congenital abnormalities? The most detailed study in this respect (6) showed a malformation rate of 3.3% for ICSI, which was similar to figures from national registries for spontaneous pregnancies. Similar malformation rate (3.6%) was reported for IVF cycles (7) . Performing ICSI will result in a higher cost for a patient who would have good fertilization without ICSI. However, it is definitely cost-saving for a patient who may have very low fertilization or no fertilization without ICSI. This matter will have to be discussed with the couple in order to arrive at an informed consent.
In a laboratory where ICSI is performed for every IVF cycle, the general level of expertise and dexterity of the embryologists will improve. This is an additional benefit of performing ICSI on some of the oocytes of all patients. Are there subgroups of patients that may benefit from ICSI, that is, those with infertility of undetermined cause versus tubal disease? Aboulghar et al. (2) reported earlier that ICSI did not help patients with tubal disease. However, Khamsi et al. (5) had at least one patient with tubal cause who had no fertilization with standard IVF insemination (0/6) versus 50% (4/8) fertilization for sibling oocytes subjected to ICSI. The controlled studies of Khamsi et al. (5) are ongoing, and eventually an analysis could be made pertaining to patients with each cause of infertility.
Intracytoplasmic sperm injection may now have a role in IVF cycles offered to patients with nonmale-factor infertility. Whether success with ICSI is related to abnormalities of spermatozoa or oocyte can only be the subject of speculation now, but this can be further investigated by more detailed examination of the spermatozoa and oocytes of the patients using techniques such as electron microscopy.
